BIO-TECHNE Corp 8-K

What Happened

• Bio-Techne Corporation announced on Feb 11, 2026 that Dr. Matt McManus will transition from his role as President of the Diagnostics and Spatial Biology segment effective March 1, 2026; he will remain for a period to support the transition. The Board approved the termination of Dr. McManus’s employment without cause on Feb 9, 2026, and he will be eligible for severance under his agreement.
• The company appointed Steve Crouse (age 52), currently Senior Vice President, Analytical Solutions Division, as President, Diagnostics and Spatial Biology, effective March 1, 2026. Mr. Crouse entered an employment agreement dated Feb 10, 2026 that sets his compensation and equity awards.

Key Details

• Start date: March 1, 2026 for Steve Crouse; employment agreement dated Feb 10, 2026.
• Base salary: $505,000 annually; target cash incentive: 75% of base salary.
• One-time equity at hire (grant-date values): options ~$42,500, time-vested RSUs ~$42,500, performance RSUs $85,000 (target) — total ~$170,000 at target.
• Annual equity program going forward (grant-date values): options ~$300,000, time-vested RSUs ~$300,000, performance RSUs $600,000 (target) — total ~$1.2M at target; time-based awards vest over 3–4 years; performance RSUs vest only if company goals for FY2026–FY2028 are met.
• Termination/severance: if Company terminates without Cause, following a Change in Control, or Mr. Crouse leaves for Good Reason, severance equals one year’s base salary, prorated incentive, and one year of health coverage (subject to release of claims).

Why It Matters

• This is a material executive change for Bio-Techne’s Diagnostics & Spatial Biology segment, potentially affecting strategy and execution in a key growth area. Investors should note the timing (effective March 1, 2026) and that the company has committed meaningful performance-linked equity to align the new segment leader with multi-year goals.
• The employment terms create potential future cash and equity dilution obligations (notably the ongoing ~$1.2M/year in grant-date equity value at target and severance obligations), which are relevant to governance and compensation oversight but are performance-contingent and subject to vesting schedules.